GSK
Executive Summary
GSK is a major UK-based multinational pharmaceutical company with global operations and a diversified portfolio spanning pharmaceuticals, vaccines, and consumer healthcare. The company has significant presence in China through local subsidiaries and partnerships, but maintains clear BIOSECURE status with no current regulatory restrictions. GSK typically pursues strategic partnerships and licensing deals aligned with its core therapeutic focus areas including oncology, immunology, respiratory, and infectious diseases.
Structure: GSK operates as a traditional multinational pharmaceutical company headquartered in London with subsidiaries and joint ventures globally. The company's Chinese operations are structured through wholly-owned subsidiaries rather than VIE structures, which simplifies due diligence and regulatory compliance for US partnerships.
Ownership & Shareholder Structure
Hengrui Medicine → GSK
GSK-Hengrui ~$12B multi-asset licensing (Jul 2025). 12 programs. $500M upfront.
BIOSECURE Risk
GSK is a UK-headquartered multinational with clear BIOSECURE status and no current regulatory restrictions
Mitigation: No specific BIOSECURE mitigation required given clear status
BD Intelligence
Therapeutic Areas:
Recent Deals: No specific deal activity data available in provided information
Approach: Direct engagement through established BD channels - GSK is a sophisticated partner with proven deal execution capabilities and clear regulatory standing
Red Flags
- ⚠Limited visibility into current pipeline priorities and recent deal activity based on available data
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 2
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.